Null Hypothesis:
Dapsone has no effects for Alzheimer's disease.
Dapsone and promine etc, were no effects for Alzheimer's disease.
답손은 알츠하이머병에 효과 없다고 주장하는 논문
Japan has developed an acetylcholine esterase inhibitor according to the hypothesis of a memory enhancement by acetylcholine.
일본은 아세틸콜린 기억 증진 가설로서 아세틸콜린에스터라제 인히비터를 개발한다
Aricept development by Hachiro Sugimoto at Eisai Co Ltd. Aricept was a drug with serious side effects.
아리셉트는 심각한 부작용이 있는 약물이었다.
Mapping the Progress of Alzheimer’s and Parkinson’s Disease pp 193-198
The New Generation of Acetylcholinesterase Inhibitor
Hachiro Sugimoto
Yoichi Iimura
Yoshiharu Yamanishi
Part of the Advances in Behavioral Biology book series (ABBI, volume 51)
Abstract
Acetylcholinesterase inhibitor has been widely recognized as an effective treatment for Alzheimer’s Disease (AD). It is known to alleviate the symptoms and slow the progression of the disease. Currently, there are four such kind of drugs in the market. These are Tacrine, Rivastigmine, Galantamine and Donepezil. Donepezil, developed by my company, Eisai Co., Ltd., was the second drug approved by the U.S. FDA for the treatment of AD.
Research papers and patents of Sugimoto teams at ESAI
에자이사의 하치로 수기모토 박사팀의 연구 논문과 특허
1. Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds, Hachiro Sugimoto, Youichi Iimura, Yoshiharu Yamanishi, Kiyomi Yamatsu, J. Med. Chem. 1995, 38, 24, 4821-4829, https://doi.org/10.1021/jm00024a009
2. US4895841A, Cyclic amine compounds with activity against acetylcholinesterase,
Inventor: Hachiro Sugimoto, Yutaka Tsuchiya, Kunizou Higurashi, Norio Karibe, Youichi Iimura, Atsushi Sasaki, Yoshiharu Yamanishi, Hiroo Ogura, Shin Araki, Takashi Kosasa, Atsuhiko Kubota, Michiko Kosasa, Kiyomi Yamatsu
3. Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors, Sugimoto, H.; Yamanish, Y.; Iimura, Y.; Kawakami, Y., Current Medicinal Chemistry, Volume 7, Number 3, 2000, pp. 303-339(37), Bentham Science Publishers, https://doi.org/10.2174/0929867003375191
도네페질을 최초 수입한 한국의 제약회사는 서울대학교병원 구매 회사를 운영하고 있었다. 서울대학교병원에서 처방전이 발행되면 한국의 모든 병원의 처방에 반영된다. 한국 국민은 약물 부작용으로부터 안전을 보호받지 못하고 있다.
This is presumed to be because a Korean pharmaceutical company imported Donepezil runs a purchasing company at Seoul National University Hospital. As a result, the Korean people are not protected from drug side effects.
KiSTi 한국과학기술정보연구원 - 치매치료제 2002. 12 발간
KiSTi (Korea Institute of Science and Technology Information)
-Publication of dementia treatments 2002. 12
치매치료제.pdf오히려 한국에서는 건강한 사람이 donepezil 복용 후 부작용이 있는가 없는가에 대한 임상 약리 연구가 수행된다.
Rather, in Korea, clinical pharmacological studies are conducted on whether healthy people have any side effects after taking donepezil.
체계적인 약물 부작용에 대한 연구는 한국에서 없었다. 약물 부작용에 대한 연구는 한국에서 없었다. 도네페질을 최초 수입한 한국의 제약회사는 서울대학교병원 구매 회사를 운영하고 있었다. 서울대학교병원에서 처방전이 발행되면 한국의 모든 병원의 처방에 반영된다. 한국 국민은 약물 부작용으로부터 안전을 보호받지 못하고 있다.
There were no systemic studies on drug side effects in Korea. This is presumed to be because a Korean pharmaceutical company that imported Donepezil runs a purchasing company at Seoul National University Hospital. The Korean people are not protected from drug side effects.